Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 1
1965 4
1966 8
1967 18
1968 37
1969 34
1970 42
1971 77
1972 73
1973 88
1974 105
1975 92
1976 78
1977 72
1978 55
1979 73
1980 62
1981 71
1982 75
1983 73
1984 78
1985 139
1986 108
1987 107
1988 127
1989 140
1990 130
1991 161
1992 170
1993 195
1994 224
1995 221
1996 238
1997 252
1998 291
1999 306
2000 328
2001 396
2002 425
2003 523
2004 551
2005 626
2006 701
2007 782
2008 838
2009 973
2010 1032
2011 1036
2012 1177
2013 1371
2014 1493
2015 1564
2016 1664
2017 1891
2018 1932
2019 1945
2020 2047
2021 1859
2022 1438
2023 1247
2024 621

Text availability

Article attribute

Article type

Publication date

Search Results

28,862 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Glucose metabolism disease"
Page 1
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement.
Battelino T, Alexander CM, Amiel SA, Arreaza-Rubin G, Beck RW, Bergenstal RM, Buckingham BA, Carroll J, Ceriello A, Chow E, Choudhary P, Close K, Danne T, Dutta S, Gabbay R, Garg S, Heverly J, Hirsch IB, Kader T, Kenney J, Kovatchev B, Laffel L, Maahs D, Mathieu C, Mauricio D, Nimri R, Nishimura R, Scharf M, Del Prato S, Renard E, Rosenstock J, Saboo B, Ueki K, Umpierrez GE, Weinzimer SA, Phillip M. Battelino T, et al. Lancet Diabetes Endocrinol. 2023 Jan;11(1):42-57. doi: 10.1016/S2213-8587(22)00319-9. Epub 2022 Dec 6. Lancet Diabetes Endocrinol. 2023. PMID: 36493795 Review.
Randomised controlled trials and other prospective clinical studies for novel medical interventions in people with diabetes have traditionally reported HbA(1c) as the measure of average blood glucose levels for the 3 months preceding the HbA(1c) test date. .. …
Randomised controlled trials and other prospective clinical studies for novel medical interventions in people with diabetes ha …
Treatment of Diabetic Kidney Disease: Current and Future.
Yamazaki T, Mimura I, Tanaka T, Nangaku M. Yamazaki T, et al. Diabetes Metab J. 2021 Jan;45(1):11-26. doi: 10.4093/dmj.2020.0217. Epub 2021 Jan 22. Diabetes Metab J. 2021. PMID: 33508907 Free PMC article. Review.
In 2019, sodium-glucose cotransporter 2 (SGLT2) inhibitor showed efficacy against DKD in Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, adding a new treatment option. ...Furthermore, NF-E2-related …
In 2019, sodium-glucose cotransporter 2 (SGLT2) inhibitor showed efficacy against DKD in Canagliflozin and Renal Events in Diabetes w …
Berberine and Its Role in Chronic Disease.
Cicero AF, Baggioni A. Cicero AF, et al. Adv Exp Med Biol. 2016;928:27-45. doi: 10.1007/978-3-319-41334-1_2. Adv Exp Med Biol. 2016. PMID: 27671811 Review.
In humans, its lipid-lowering and insulin-resistance improving actions have clearly been demonstrated in numerous randomized clinical trials. Moreover, preliminary clinical evidence suggest the ability of berberine to reduce endothelial inflammation improving …
In humans, its lipid-lowering and insulin-resistance improving actions have clearly been demonstrated in numerous randomized clini …
Gut Microbiome Fermentation Determines the Efficacy of Exercise for Diabetes Prevention.
Liu Y, Wang Y, Ni Y, Cheung CKY, Lam KSL, Wang Y, Xia Z, Ye D, Guo J, Tse MA, Panagiotou G, Xu A. Liu Y, et al. Cell Metab. 2020 Jan 7;31(1):77-91.e5. doi: 10.1016/j.cmet.2019.11.001. Epub 2019 Nov 27. Cell Metab. 2020. PMID: 31786155 Free article. Clinical Trial.
Exercise is an effective strategy for diabetes management but is limited by the phenomenon of exercise resistance (i.e., the lack of or the adverse response to exercise on metabolic health). Here, in 39 medication-naive men with prediabetes, we found that exercise-induced …
Exercise is an effective strategy for diabetes management but is limited by the phenomenon of exercise resistance (i.e., the lack of or the …
Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy.
Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Abdel-Wahab AF, et al. Pharmacol Res. 2019 Dec;150:104511. doi: 10.1016/j.phrs.2019.104511. Epub 2019 Oct 31. Pharmacol Res. 2019. PMID: 31678210 Review.
Most solid tumor cells adapt to their heterogeneous microenvironment by depending largely on aerobic glycolysis for energy production, a phenomenon called the Warburg effect, which is a hallmark of cancer. The altered energy metabolism not only provides cancer cell with AT …
Most solid tumor cells adapt to their heterogeneous microenvironment by depending largely on aerobic glycolysis for energy production, a phe …
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Heerspink HJ, et al. Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28. Circulation. 2016. PMID: 27470878 Review.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic therapies. ...In contrast, blood pressure lowering, estimated glomerular filtration rate, and albuminuric effects are pre …
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are now widely approved …
A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications.
Huang DD, Shi G, Jiang Y, Yao C, Zhu C. Huang DD, et al. Biomed Pharmacother. 2020 May;125:109767. doi: 10.1016/j.biopha.2019.109767. Epub 2020 Feb 12. Biomed Pharmacother. 2020. PMID: 32058210 Free article. Review.
Diabetes mellitus (DM) is a major world health problem and one of the most studied diseases, which are highly prevalent in the whole world, it is frequently associated with severe clinical complications, such as diabetic cardiomyopathy, nephropathy, retinopathy, neu …
Diabetes mellitus (DM) is a major world health problem and one of the most studied diseases, which are highly prevalent in the whole …
Therapeutic mechanisms of traditional Chinese medicine to improve metabolic diseases via the gut microbiota.
Zhang HY, Tian JX, Lian FM, Li M, Liu WK, Zhen Z, Liao JQ, Tong XL. Zhang HY, et al. Biomed Pharmacother. 2021 Jan;133:110857. doi: 10.1016/j.biopha.2020.110857. Epub 2020 Nov 13. Biomed Pharmacother. 2021. PMID: 33197760 Free article.
Metabolic diseases such as obesity, type 2 diabetes mellitus, and hyperlipidemia are associated with the dysfunction of gut microbiota. ...In particular, we focused on the protection of the intestinal barrier function, modulation of metabolic endotoxemia and …
Metabolic diseases such as obesity, type 2 diabetes mellitus, and hyperlipidemia are associated with the dysfunction of gut mi …
Perioperative glycaemic control for people with diabetes undergoing surgery.
Bellon F, Solà I, Gimenez-Perez G, Hernández M, Metzendorf MI, Rubinat E, Mauricio D. Bellon F, et al. Cochrane Database Syst Rev. 2023 Aug 1;8(8):CD007315. doi: 10.1002/14651858.CD007315.pub3. Cochrane Database Syst Rev. 2023. PMID: 37526194 Review.
BACKGROUND: People with diabetes mellitus are at increased risk of postoperative complications. Data from randomised clinical trials and meta-analyses point to a potential benefit of intensive glycaemic control, targeting near-normal blood glucose, in people …
BACKGROUND: People with diabetes mellitus are at increased risk of postoperative complications. Data from randomised clinical …
Efficacy and safety of prolonged water fasting: a narrative review of human trials.
Ezpeleta M, Cienfuegos S, Lin S, Pavlou V, Gabel K, Varady KA. Ezpeleta M, et al. Nutr Rev. 2024 Apr 12;82(5):664-675. doi: 10.1093/nutrit/nuad081. Nutr Rev. 2024. PMID: 37377031 Review.
With regard to adverse events, metabolic acidosis, headaches, insomnia, and hunger were observed in some studies. ...However, the ability of these protocols to produce sustained improvements in metabolic markers warrants further investigation....
With regard to adverse events, metabolic acidosis, headaches, insomnia, and hunger were observed in some studies. ...However, the abi …
28,862 results
You have reached the last available page of results. Please see the User Guide for more information.